CD19 and lymphoma: Anti-CD19 CAR-modified CIML NK cells displayed significantly increased interferon-γ (IFNγ) secretion and cytotoxicity against NK-resistant lymphoma lines and primary lymphoma tumor cells, and significantly reduced lymphoma burden and significantly improved the survival in human lymphoma xenograft models [91].